Sign in or Register   Sign in or Register
  |  

Mouse Anti-FHL1 Recombinant Antibody (2F7) (CBMAB-A2982-LY)

The product is antibody recognizes FHL1. The antibody 2F7 immunoassay techniques such as: WB, ELISA.
See all FHL1 antibodies
Published Data

Summary

Host Animal
Mouse
Specificity
Human, Rat
Clone
2F7
Antibody Isotype
IgG2a, κ
Application
WB, ELISA

Basic Information

Immunogen
FHL1 (NP_001440, 23 a.a. ~ 120 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Specificity
Human, Rat
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
four and a half LIM domains 1
Introduction
LIM proteins, named for 'LIN11, ISL1, and MEC3,' are defined by the possession of a highly conserved double zinc finger motif called the LIM domain.[supplied by OMIM
Entrez Gene ID
Human2273
Rat25177
UniProt ID
HumanQ13642
RatQ9WUH4
Alternative Names
FHL1B; FLH1A; KYO-T; MGC111107; SLIM1; XMPMA; bA535K18.1
Function
May have an involvement in muscle development or hypertrophy.
Biological Process
Animal organ morphogenesis Source: UniProtKB
Cell differentiation Source: UniProtKB-KW
Muscle organ development Source: UniProtKB
Negative regulation of cell growth Source: UniProtKB
Negative regulation of G1/S transition of mitotic cell cycle Source: UniProtKB
Negative regulation of G2/M transition of mitotic cell cycle Source: UniProtKB
Positive regulation of potassium ion transport Source: BHF-UCL
Regulation of membrane depolarization Source: BHF-UCL
Regulation of potassium ion transmembrane transporter activity Source: BHF-UCL
Cellular Location
Isoform 1: Cytoplasm
Isoform 2: Cytosol; Nucleus. Predominantly nuclear in myoblasts but is cytosolic in differentiated myotubes.
Involvement in disease
Emery-Dreifuss muscular dystrophy 6, X-linked (EDMD6):
A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.
Scapuloperoneal myopathy, X-linked dominant (SPM):
A disease characterized by progressive muscle weakness and wasting, upper and lower limbs weakness, foot drop, scapular winging, and myopathic changes on muscle biopsy. Most affected individuals become wheelchair-bound.
Myopathy, X-linked, with postural muscle atrophy (XMPMA):
A progressive muscular dystrophy with onset in adulthood. Affected individuals develop a proximal myopathy characterized by specific atrophy of postural muscles, limited neck flexion, bent spine, contractures of the Achilles tendon, respiratory problems, and cardiomyopathy. Patients may show muscle hypertrophy in the early stages of the disorder.
Reducing body myopathy, X-linked 1A, severe, with infantile or early childhood onset (RBMX1A):
A rare myopathy clinically characterized by rapidly progressive muscular weakness, and pathologically by the presence of intracytoplasmic inclusion bodies strongly stained by menadione-linked alpha-glycerophosphate dehydrogenase in the absence of substrate, alpha-glycerophosphate. The term 'reducing body' refers to the reducing activity of the inclusions to nitroblue tetrazolium in the absence of substrate. This condition is also commonly associated with rimmed vacuoles and cytoplasmic bodies. Death in childhood is frequent in the severe form of the disease, due to respiratory failure.
Reducing body myopathy, X-linked 1B, with late childhood or adult onset (RBMX1B):
A rare myopathy clinically characterized by rapidly progressive muscular weakness, and pathologically by the presence of intracytoplasmic inclusion bodies strongly stained by menadione-linked alpha-glycerophosphate dehydrogenase in the absence of substrate, alpha-glycerophosphate. The term 'reducing body' refers to the reducing activity of the inclusions to nitroblue tetrazolium in the absence of substrate. This condition is also commonly associated with rimmed vacuoles and cytoplasmic bodies.
Uruguay faciocardiomusculoskeletal syndrome (FCMSU):
An X-linked recessive syndrome characterized by brachyturricephaly, pugilistic coarse facies, a muffled voice, cardiomyopathy, muscular hypertrophy, broad hands, wide feet with progressive pes cavus deformities, dislocation of toes, variable congenital hip dislocation, and scoliosis.
Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-FHL1 Recombinant Antibody (2F7)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare